Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 59Cholangiocarcinoma 19Carcinoma, Renal Cell 16Biliary Tract Neoplasms 11Stomach Neoplasms 9Thyroid Neoplasms 8Endometrial Neoplasms 8Parkinson Disease 4, Autosomal Dominant Lewy Body 7Neoplasms 7Melanoma 6Uterine Cervical Neoplasms 5Thyroid Carcinoma, Anaplastic 5Neuroendocrine Tumors 5Carcinoma, Non-Small-Cell Lung 5Recurrence 4Ovarian Neoplasms 4Liver Neoplasms 4Thyroid Cancer, Papillary 3Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Neoplasm Metastasis 3Cirrhosis, Familial, with Pulmonary Hypertension 3Brain Neoplasms 3Advanced Biliary Tract Cancer 3Adenocarcinoma, Follicular 3Vulvar Neoplasms 2Uveal Melanoma 2Triple Negative Breast Neoplasms 2Thymoma 2Solid Tumors 2

Interventions

Ipilimumab 6tremelimumab 4durvalumab 3Nivolumab 3Bevacizumab 3balstilimab 2Paclitaxel 2Cisplatin 2Capecitabine 2relatlimab 1lenvatinib 1folfirinox 1Vaccines 1Standard of Care 1Radiotherapy 1Radiofrequency Ablation 1Radiation 1Platinum 1Pemetrexed 1Opdualag 1Cryosurgery 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Diabetes Mellitus, Insulin-Dependent, 12 × lenvatinib × Clear all
NCT07131501 2025-08-20

A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Not yet recruiting
48 enrolled
Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡